How many boxes of Erdafitinib should be taken in a month?

Erdafitinib (Erdafitinib) received accelerated approval on April 12, 2019, for the treatment of patients with metastatic or locally advanced urothelial carcinoma who have predisposing fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations and have progressed during or after at least one line of platinum-based chemotherapy. As a result, it became the first targeted therapy for metastatic bladder cancer approved by the FDA.

In the BLC2001 trial, erdafitinib had an overall efficacy rate of 40% in patients with urothelial cancer. Common adverse events include hyperphosphatemia and retinopathy, which require regular monitoring. Although increases in serum phosphate levels have been identified as a pharmacodynamic marker of response, further interrogation of other clinical, genomic, and transcriptomic biomarkers is warranted. Patients can take 8 mg (Two tablets4mg tablets) or 9mg (Three tablets3mg tablets) once a day. The common specifications per box are 4mg*14 tablets. It is estimated that patients may need to take about 5.6 boxes a month, and calculations need to be made based on the patient's condition.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).